Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2007

01.09.2007 | Original Paper

Low dentin matrix protein 1 expression correlates with skeletal metastases development in breast cancer patients and enhances cell migratory capacity in vitro

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Small integrin-binding ligand N-linked glycoproteins (SIBLINGs) constitute a family of extracellular matrix proteins involved in bone homeostasis. Their pattern of expression has been primarily reported in bone and tooth and, more recently, in several cancer types. Dentin matrix protein 1 (DMP1), a SIBLING family member, expression was investigated by immunohistochemistry in a retrospective series of 148 primary human breast cancers. Correlations between DMP1 expression levels in the tumors and clinicopathologic features, bone metastases development and relapse of the disease were examined. DMP1 was expressed by 63.5% of the breast tumors analyzed. Significant inverse associations were found between DMP1 expression levels and the size and grade of the tumors (both, P < 0.0001). High DMP1 expression levels in the primary breast lesions were associated with a lower risk of subsequent development of skeletal metastases (P = 0.009). Patients with tumors expressing high levels of DMP1 had a significantly higher disease-free survival rate than those with low DMP1-expressing tumors (P = 0.0062). When DMP1 expression was examined in breast cancer cell lines, we found that non invasive MCF-7 and T47-D cells expressed higher levels than highly invasive MDA-MB-231 and Hs578T cells. Moreover, the specific inhibition of DMP1 expression in MCF-7 cells using siRNAs promoted significantly their migratory capability. Our data implicate for the first time DMP1 expression in breast cancer progression and bone metastases development.
Literatur
1.
Zurück zum Zitat Fisher LW, Fedarko NS (2003) Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44:33–40PubMedCrossRef Fisher LW, Fedarko NS (2003) Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44:33–40PubMedCrossRef
2.
Zurück zum Zitat Brown LF, Berse B, Van De Water L, Papadopoulos-Sergiou A, Peruzzi CA, Manseau EJ, Dvorak HF, Senger DR (1992) Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 3:1169–1180PubMed Brown LF, Berse B, Van De Water L, Papadopoulos-Sergiou A, Peruzzi CA, Manseau EJ, Dvorak HF, Senger DR (1992) Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 3:1169–1180PubMed
3.
Zurück zum Zitat Brown LF, Papadopoulos SA, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610–623PubMed Brown LF, Papadopoulos SA, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610–623PubMed
4.
Zurück zum Zitat Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190PubMedCrossRef Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190PubMedCrossRef
5.
Zurück zum Zitat Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90:1877–1881PubMedCrossRef Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90:1877–1881PubMedCrossRef
6.
Zurück zum Zitat Bellahcène A, Merville M-P, Castronovo V (1994) Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 54:2823–2826PubMed Bellahcène A, Merville M-P, Castronovo V (1994) Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 54:2823–2826PubMed
7.
Zurück zum Zitat Waltregny D, Bellahcène A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewé W, de Leval J, Castronovo V (1998) Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Nat Cancer Inst 90:1000–1008PubMedCrossRef Waltregny D, Bellahcène A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewé W, de Leval J, Castronovo V (1998) Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Nat Cancer Inst 90:1000–1008PubMedCrossRef
8.
Zurück zum Zitat Bellahcène A, Albert V, Basolo F, Pollina L, Fisher LW, Castronovo V (1998) Ectopic expression of bone sialoprotein in thyroid human cancer. Thyroid 8:637–641PubMedCrossRef Bellahcène A, Albert V, Basolo F, Pollina L, Fisher LW, Castronovo V (1998) Ectopic expression of bone sialoprotein in thyroid human cancer. Thyroid 8:637–641PubMedCrossRef
9.
Zurück zum Zitat Bellahcène A, Maloujahmoum N, Fisher LW, Pastorino H, Tagliabue E, Ménard S, Castronovo V (1997) Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 61:183–188PubMedCrossRef Bellahcène A, Maloujahmoum N, Fisher LW, Pastorino H, Tagliabue E, Ménard S, Castronovo V (1997) Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 61:183–188PubMedCrossRef
10.
Zurück zum Zitat Detry C, Waltregny D, Quatresooz P, Chaplet M, Kedzia W, Castronovo V, Delvenne P, Bellahcene A (2003) Detection of bone sialoprotein in human (pre)neoplastic lesions of the uterine cervix. Calcif Tissue Int 73:9–14PubMedCrossRef Detry C, Waltregny D, Quatresooz P, Chaplet M, Kedzia W, Castronovo V, Delvenne P, Bellahcene A (2003) Detection of bone sialoprotein in human (pre)neoplastic lesions of the uterine cervix. Calcif Tissue Int 73:9–14PubMedCrossRef
11.
Zurück zum Zitat Bellahcène A, Van Riet I, de Greef C, Antoine N, Young MF, Van Camp B, Castronovo V (2000) Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients. Br J Haematol 111:1118–1121PubMedCrossRef Bellahcène A, Van Riet I, de Greef C, Antoine N, Young MF, Van Camp B, Castronovo V (2000) Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients. Br J Haematol 111:1118–1121PubMedCrossRef
12.
Zurück zum Zitat Bellahcène A, Kroll M, Liebens F, Castronovo V (1996) Bone sialoprotein detection in human breast cancer cells: a potential predictor of bone metastases. J Bone Min Res 11:665–670CrossRef Bellahcène A, Kroll M, Liebens F, Castronovo V (1996) Bone sialoprotein detection in human breast cancer cells: a potential predictor of bone metastases. J Bone Min Res 11:665–670CrossRef
13.
Zurück zum Zitat Bellahcène A, Menard S, Bufalino R, Moreau L, Castronovo V (1996) Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69:350–353PubMedCrossRef Bellahcène A, Menard S, Bufalino R, Moreau L, Castronovo V (1996) Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69:350–353PubMedCrossRef
14.
Zurück zum Zitat Waltregny D, Bellahcène A, de Leval X, Florkin B, Weidle U, Castronovo V (2000) Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15:834–843PubMedCrossRef Waltregny D, Bellahcène A, de Leval X, Florkin B, Weidle U, Castronovo V (2000) Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15:834–843PubMedCrossRef
15.
Zurück zum Zitat Chaplet M, Waltregny D, Detry C, Fisher LW, Castronovo V, Bellahcène A (2006) Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness. Int J Cancer 118:850–856PubMedCrossRef Chaplet M, Waltregny D, Detry C, Fisher LW, Castronovo V, Bellahcène A (2006) Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness. Int J Cancer 118:850–856PubMedCrossRef
16.
Zurück zum Zitat Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL (2000) MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54–68PubMedCrossRef Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL (2000) MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54–68PubMedCrossRef
17.
Zurück zum Zitat Ogbureke KU, Fisher LW (2004) Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res 83:664–670PubMedCrossRef Ogbureke KU, Fisher LW (2004) Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res 83:664–670PubMedCrossRef
18.
Zurück zum Zitat Ogbureke KU, Fisher LW (2005) Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int 68:155–166PubMedCrossRef Ogbureke KU, Fisher LW (2005) Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int 68:155–166PubMedCrossRef
19.
Zurück zum Zitat Chaplet M, De Leval L, Waltregny D, Detry C, Fornaciari G, Bevilacqua G, Fisher LW, Castronovo V, Bellahcène A (2003) Dentin matrix protein 1 is expressed in human lung cancer. J Bone Miner Res 18:1506–1512PubMedCrossRef Chaplet M, De Leval L, Waltregny D, Detry C, Fornaciari G, Bevilacqua G, Fisher LW, Castronovo V, Bellahcène A (2003) Dentin matrix protein 1 is expressed in human lung cancer. J Bone Miner Res 18:1506–1512PubMedCrossRef
20.
Zurück zum Zitat Fisher LW, Jain A, Tayback M, Fedarko NS (2004) Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 10:8501–8511PubMedCrossRef Fisher LW, Jain A, Tayback M, Fedarko NS (2004) Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 10:8501–8511PubMedCrossRef
21.
Zurück zum Zitat World Health Organization (1982) Histological typing of breast tumors. Tumori 68:181–198 World Health Organization (1982) Histological typing of breast tumors. Tumori 68:181–198
22.
Zurück zum Zitat Elston C, Ellis I (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology 19:403–410PubMedCrossRef Elston C, Ellis I (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology 19:403–410PubMedCrossRef
23.
Zurück zum Zitat Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS (2002) Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H’s cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 277:13700–13708PubMedCrossRef Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS (2002) Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H’s cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 277:13700–13708PubMedCrossRef
24.
Zurück zum Zitat Chaplet M, Detry C, Deroanne C, Fisher LW, Castronovo V, Bellahcene A (2004) Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem J 384:591–598PubMedCrossRef Chaplet M, Detry C, Deroanne C, Fisher LW, Castronovo V, Bellahcene A (2004) Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem J 384:591–598PubMedCrossRef
25.
Zurück zum Zitat Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5:3914–3919PubMed Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5:3914–3919PubMed
26.
Zurück zum Zitat Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060–4066PubMed Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060–4066PubMed
27.
Zurück zum Zitat Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417–3427PubMed Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417–3427PubMed
28.
Zurück zum Zitat Donati V, Boldrini L, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11:6459–6465PubMedCrossRef Donati V, Boldrini L, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11:6459–6465PubMedCrossRef
29.
Zurück zum Zitat Fedarko NS, Fohr B, Fisher LW (2000) DMP-1 inactivates complement by bridging Factor H to cell surface receptors. J Dent Res 79:339 Fedarko NS, Fohr B, Fisher LW (2000) DMP-1 inactivates complement by bridging Factor H to cell surface receptors. J Dent Res 79:339
30.
Zurück zum Zitat Bellahcène A, Bonjean K, Fohr B, Fedarko NS, Robey FA, Young MF, Fisher LW, Castronovo V (2000) Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ Res 86:885–891PubMed Bellahcène A, Bonjean K, Fohr B, Fedarko NS, Robey FA, Young MF, Fisher LW, Castronovo V (2000) Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ Res 86:885–891PubMed
31.
Zurück zum Zitat Leali D, Dell’Era P, Stabile H, Sennino B, Chambers AF, Naldini A, Sozzani S, Nico B, Ribatti D, Presta M (2003) Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol 171:1085–1093PubMed Leali D, Dell’Era P, Stabile H, Sennino B, Chambers AF, Naldini A, Sozzani S, Nico B, Ribatti D, Presta M (2003) Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol 171:1085–1093PubMed
32.
Zurück zum Zitat Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, Shimanuki Y, Nishio K, Fukuchi Y (2003) Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 198:107–117PubMedCrossRef Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, Shimanuki Y, Nishio K, Fukuchi Y (2003) Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 198:107–117PubMedCrossRef
33.
Zurück zum Zitat Fedarko NS, Jain A, Karadag A, Fisher LW (2004) Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. Faseb J 18:734–736PubMed Fedarko NS, Jain A, Karadag A, Fisher LW (2004) Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. Faseb J 18:734–736PubMed
34.
Zurück zum Zitat Karadag A, Fedarko NS, Fisher LW (2005) Dentin matrix protein 1 enhances invasion potential of colon cancer cells by bridging matrix metalloproteinase-9 to integrins and CD44. Cancer Res 65:11545–11552PubMedCrossRef Karadag A, Fedarko NS, Fisher LW (2005) Dentin matrix protein 1 enhances invasion potential of colon cancer cells by bridging matrix metalloproteinase-9 to integrins and CD44. Cancer Res 65:11545–11552PubMedCrossRef
35.
Zurück zum Zitat Karadag A, Ogbureke KU, Fedarko NS, Fisher LW (2004) Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 96:956–965PubMedCrossRef Karadag A, Ogbureke KU, Fedarko NS, Fisher LW (2004) Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 96:956–965PubMedCrossRef
36.
Zurück zum Zitat Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174PubMedCrossRef Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174PubMedCrossRef
37.
Zurück zum Zitat Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M (2001) Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 84:1488–1496PubMedCrossRef Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M (2001) Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 84:1488–1496PubMedCrossRef
38.
Zurück zum Zitat Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10:7621–7628PubMedCrossRef Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10:7621–7628PubMedCrossRef
39.
Zurück zum Zitat Remacle AG, Noel A, Duggan C, McDermott E, O’Higgins N, Foidart JM, Duffy MJ (1998) Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77:926–931PubMed Remacle AG, Noel A, Duggan C, McDermott E, O’Higgins N, Foidart JM, Duffy MJ (1998) Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77:926–931PubMed
40.
Zurück zum Zitat Talvensaari-Mattila A, Turpeenniemi-Hujanen T (2005) Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett 217:237–242PubMedCrossRef Talvensaari-Mattila A, Turpeenniemi-Hujanen T (2005) Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett 217:237–242PubMedCrossRef
41.
Zurück zum Zitat Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ (2005) CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11:3309–3314PubMedCrossRef Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ (2005) CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11:3309–3314PubMedCrossRef
Metadaten
Titel
Low dentin matrix protein 1 expression correlates with skeletal metastases development in breast cancer patients and enhances cell migratory capacity in vitro
Publikationsdatum
01.09.2007
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2007
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9436-0

Weitere Artikel der Ausgabe 1/2007

Breast Cancer Research and Treatment 1/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.